Ann Varanakis Sells 50,000 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Ann Varanakis sold 50,000 shares of LifeStance Health Group stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the sale, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This represents a 13.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

LifeStance Health Group Stock Performance

NASDAQ LFST traded up $0.11 on Friday, hitting $7.05. The stock had a trading volume of 9,306,414 shares, compared to its average volume of 2,042,345. The company’s 50-day moving average is $5.95 and its two-hundred day moving average is $5.37. LifeStance Health Group, Inc. has a one year low of $3.74 and a one year high of $8.30. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -235.00 and a beta of 1.13. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company had revenue of $363.81 million for the quarter, compared to analysts’ expectations of $355.06 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The business’s revenue for the quarter was up 16.3% compared to the same quarter last year. On average, analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on LFST. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday. UBS Group raised their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen lowered shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.83.

Hedge Funds Weigh In On LifeStance Health Group

Several large investors have recently made changes to their positions in LFST. Bayesian Capital Management LP acquired a new stake in shares of LifeStance Health Group in the second quarter worth $52,000. Park Edge Advisors LLC purchased a new stake in LifeStance Health Group in the 2nd quarter worth about $52,000. Vanguard Personalized Indexing Management LLC acquired a new stake in LifeStance Health Group during the 3rd quarter worth about $72,000. Blair William & Co. IL purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $70,000. Finally, Public Employees Retirement System of Ohio purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $70,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.